Factors Affecting Final Adult Height in Patients with Turner Syndrome / 소아과

ABSTRACT

PURPOSE: Short stature is one of the characteristic features of Turner syndrome. We investigated the factors affecting final adult height(FAH) in patients with Turner syndrome. METHODS: The study group was comprised of 60 patients who were diagnosed with Turner syndrome by chromosomal study and clinical phenotypes and attained FAH. Data were obtained from retrospective review of the medical records. We analyzed the factors influencing FAH in growth hormone(GH) treated and GH untreated groups. RESULTS: Sixty patients were enrolled; 48 patients received GH treatment, and 12 patients did not. Mean duration of GH treatment was 35.8 months(range 4 to 120 months), and mean dosage of GH was 0.8+/-0.2 IU/kg/wk in GH treated group. Mean growth velocity was 5.6+/-2.0 cm/yr, which was significantly higher than that during pretreatment period. In the GH treated group, mean chronological age, bone age, mean height, and height standard deviation(SD) score at GH treatment were 12.2+/-2.7 yr, 10.3+/-2.5 yr, 127.5+/-10.1 cm and -3.1+/-1.1, respectively. In the GH treated group, the mean FAH and SD score of FAH were 146.9+/-5.8 cm and -2.7+/-1.2, respectively, which showed significant differences compared with those of the GH untreated group. Analyzing the factors affecting FAH in GH-treated patients, only the SD score of height at the time of treatment was significantly related to FAH. CONCLUSION: GH treatment leads to an increment in FAH in patients with Turner syndrome. Average FAH gain was as much as 5.8 cm. SD score of height at the time of GH treatment was the only factor influencing FAH.